These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 11848550)
21. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia. Paus E; Nilsson O; Børmer OP; Fosså SD; Otnes B; Skovlund E J Urol; 1998 May; 159(5):1599-605. PubMed ID: 9554362 [TBL] [Abstract][Full Text] [Related]
22. PSA excess in the differential diagnosis of prostate carcinoma. Díaz F; Morell M; Rojo G Arch Esp Urol; 1997 May; 50(4):415-8. PubMed ID: 9219422 [TBL] [Abstract][Full Text] [Related]
23. The use of complexed PSA for the early detection of prostate cancer. Fischer K; Loertzer H; Fornara P Anticancer Res; 2005; 25(3A):1591-6. PubMed ID: 16033065 [TBL] [Abstract][Full Text] [Related]
24. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer. Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656 [TBL] [Abstract][Full Text] [Related]
25. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters. Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872 [TBL] [Abstract][Full Text] [Related]
26. Complexed prostate-specific antigen for the detection of prostate cancer. Filella X; Truan D; Alcover J; Gutierrez R; Molina R; Coca F; Ballesta AM Anticancer Res; 2004; 24(6):4181-5. PubMed ID: 15736470 [TBL] [Abstract][Full Text] [Related]
27. [Diagnostic value of complexed prostate-specific antigen for prostate cancer]. Su HW; Li Y; Xu P Zhonghua Nan Ke Xue; 2003 Sep; 9(6):431-3. PubMed ID: 14574807 [TBL] [Abstract][Full Text] [Related]
28. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together. Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613 [TBL] [Abstract][Full Text] [Related]
30. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. Jung K; Meyer A; Lein M; Rudolph B; Schnorr D; Loening SA J Urol; 1998 May; 159(5):1595-8. PubMed ID: 9554361 [TBL] [Abstract][Full Text] [Related]
31. Total and free PSA: a methodical and clinical evaluation of five assays. Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603 [TBL] [Abstract][Full Text] [Related]
32. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA. Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429 [TBL] [Abstract][Full Text] [Related]
33. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients. Beneduce L; Prayer-Galetti T; Giustinian AM; Gallotta A; Betto G; Pagano F; Fassina G Cancer Detect Prev; 2007; 31(5):402-7. PubMed ID: 18035503 [TBL] [Abstract][Full Text] [Related]
34. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA. Wolff JM; Boeckmann W; Effert PJ; Habib FK; Jakse G Anticancer Res; 1997; 17(4B):2993-4. PubMed ID: 9329583 [TBL] [Abstract][Full Text] [Related]
35. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Nakamura T; Scorilas A; Stephan C; Jung K; Soosaipillai AR; Diamandis EP Cancer Res; 2003 Oct; 63(19):6543-6. PubMed ID: 14559849 [TBL] [Abstract][Full Text] [Related]
36. [Usefulness of PSA-complex in the diagnosis of prostatic carcinoma]. Martín Vega A; Moreno Sierra J; Ortega Heredia MD; López García-Asenjo JA; Fernández Pérez C; Redondo González E; Bocardo Fajardo G; Valor Perea R; Silmi Moyano A; Blanco Jiménez LE; Resel Estévez L Arch Esp Urol; 2000 Nov; 53(9):776-82. PubMed ID: 11196384 [TBL] [Abstract][Full Text] [Related]
37. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682 [TBL] [Abstract][Full Text] [Related]
38. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH. Abrahamsson PA; Kuriyama M Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617 [TBL] [Abstract][Full Text] [Related]
39. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. Stephan C; Kramer J; Meyer HA; Kristiansen G; Ziemer S; Deger S; Lein M; Loening SA; Jung K BJU Int; 2007 Jun; 99(6):1427-31. PubMed ID: 17355366 [TBL] [Abstract][Full Text] [Related]
40. First clinical results with Enzymun-Test for free PSA. Gilson G; Lamy S; Humbel RL Anticancer Res; 1997; 17(4B):2861-4. PubMed ID: 9329548 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]